Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients With Postherpetic Neuralgia.
Conditions
Interventions
TV-45070
Placebo
Locations
77
United States
Teva Investigational Site 13052
Birmingham, Alabama, United States
Teva Investigational Site 13086
Mobile, Alabama, United States
Teva Investigational Site 13514
Phoenix, Arizona, United States
Teva Investigational Site 13520
Phoenix, Arizona, United States
Teva Investigational Site 13661
Little Rock, Arkansas, United States
Teva Investigational Site 13079
Colton, California, United States
Start Date
February 26, 2015
Primary Completion Date
May 9, 2017
Completion Date
May 9, 2017
Last Updated
November 9, 2021
NCT06290661
NCT07000409
NCT06896994
NCT06232486
NCT06225960
NCT07399288
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions